Plasma donations could be collected using a process called
plasmapheresis. In addition to
NHS-derived factors produced by
Bio Products Laboratory (BPL), manufacturers that supplied clotting factor products to the UK during the mid-1970s and 1980s included Abbott (Profilate), Armour Pharmaceuticals (Factorate),
Bayer-owned
Cutter (Koate),
Baxter International-owned Travenol/Hyland (Hemofil/Interhem), Immuno (Kryobulin) and Speywood (Humanate). • BPL: In 2013 the British government sold an 80% stake in the company to
Bain Capital for approximately £230 million. In 2016 BPL was acquired by the Creat Group for £820m; the government stood to receive £164m from its remaining 20% share in BPL. • Armour (Revlon): In 1978 Armour was purchased by
Revlon for $90m. It owned the company until 1987, when it was sold to
Rhône-Poulenc which purchased Revlon's drug operation for $690m in cash. In 1996, Armour and Behringwerke merged, and became Centeon. In 1999, Centeon changed its name to Aventis Behring after the parent companies, Rorer and
Hoechst AG merged to become Aventis. In 2004, CSL completed its acquisition of Aventis Behring for $925m, today known as
CSL Behring. • Bayer: Cutter Labs, which produced factor VIII, was originally owned by
Miles Laboratories. In 1974, Cutter Labs was purchased by Bayer. In 1978, Bayer also purchased Miles Labs. In 1995, Bayer dropped the Miles Labs brand name. In 2005, a new company, Talecris set up by
Cerberus Capital Management and Ampersand, acquired Bayer's plasma business and assets for $590m. Bayer did not include its recombinant factor VIII "Kogenate" in the sale. "Kogenate" was discontinued in 2022. In 2009,
CSL Limited attempted to take over Talecris for $3.1 billion, but was stopped by the
Federal Trade Commission which determined the deal would be illegal. In 2011, a year after announcing the $4bn deal,
Grifols completed a takeover of Talecris. • Hyland/Travenol (Baxter): Baxter created Travenol Labs in 1949 and acquired Hyland Labs in 1952. In 1993 Baxter, was implicated in a lawsuit brought by haemophiliacs infected with HIV in the United States, and, by the end of that year, president James Tobin had quit. In 1996 Baxter settled a lawsuit brought by haemophiliacs in Japan. In 2015, Baxter split-off its haemophilia sector to create
Baxalta. In 2016 Baxalta was acquired by
Shire plc for $32bn. • Immuno AG: Baxter purchased Immuno AG in 1996 in an effort to keep up with competitors, for $715m. == Hepatitis (1973–1986) ==